Alto Neuroscience (NYSE:ANRO) Given New $44.00 Price Target at JonesTrading

Alto Neuroscience (NYSE:ANRO) had its price objective lowered by JonesTrading from $49.00 to $44.00 in a research report report published on Thursday,Benzinga reports. JonesTrading currently has a buy rating on the stock.

A number of other equities research analysts have also recently weighed in on ANRO. Wall Street Zen cut Alto Neuroscience from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Jefferies Financial Group reissued a “buy” rating and issued a $35.00 price objective on shares of Alto Neuroscience in a research note on Monday, March 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. Chardan Capital restated a “buy” rating and issued a $30.00 target price on shares of Alto Neuroscience in a research note on Thursday. Finally, BTIG Research lifted their price target on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $35.14.

Alto Neuroscience Trading Down 7.9%

Shares of ANRO stock opened at $21.57 on Thursday. The company has a market capitalization of $689.03 million, a P/E ratio of -9.89 and a beta of 2.01. Alto Neuroscience has a 12-month low of $1.60 and a 12-month high of $25.17. The company has a quick ratio of 15.69, a current ratio of 15.69 and a debt-to-equity ratio of 0.12. The firm has a 50-day moving average price of $19.18 and a 200 day moving average price of $14.68.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.11. Research analysts forecast that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently made changes to their positions in ANRO. Torren Management LLC acquired a new position in shares of Alto Neuroscience during the fourth quarter valued at $62,000. Balyasny Asset Management L.P. acquired a new stake in Alto Neuroscience in the fourth quarter worth about $198,000. OMERS ADMINISTRATION Corp bought a new stake in Alto Neuroscience during the 4th quarter worth about $221,000. Vanguard Personalized Indexing Management LLC raised its holdings in Alto Neuroscience by 13.7% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock worth $69,000 after purchasing an additional 2,055 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. acquired a new position in Alto Neuroscience during the 4th quarter valued at about $304,000.

Key Stories Impacting Alto Neuroscience

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Multiple firms reaffirmed buy/outperform views and high upside potential: HC Wainwright kept a “buy” and $50 PT, Chardan reaffirmed “buy” with $30 PT, JonesTrading maintained “buy” after lowering its PT to $44, and Robert W. Baird kept an “outperform” while trimming its PT to $38 — these show analyst conviction in Alto’s pipeline despite the miss. Analyst Notes
• Neutral Sentiment: Alto announced it will shift focus toward ALTO-207 and highlighted other pipeline updates following the ALTO-101 topline release — a strategic pivot that could preserve value if follow-on programs show promise, but it’s a longer-term catalyst. ALTO-207 Pivot
• Negative Sentiment: Topline Phase 2 results: ALTO-101 did not achieve statistical significance on the primary endpoint — the direct clinical failure is the main driver of today’s negative price action. Topline Press Release
• Negative Sentiment: Market coverage and headlines amplified the sell-off — multiple outlets reported the failed schizophrenia study and described sizable share declines in pre-market and trading sessions. Expect elevated volume and volatility as investors reassess timelines and probabilities for the rest of the pipeline. Market Reaction
• Negative Sentiment: Some firms became more cautious: Wedbush cut its PT to $21 and set a “neutral” rating — a signal that at least one analyst group sees limited near-term upside after the trial outcome. Wedbush Note

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.